Management of Rivaroxaban in Patients with Severe Renal Impairment

Introduction to Renal Impairment Considerations

• The American College of Cardiology guidelines recommend rivaroxaban 15 mg once daily for moderate renal impairment (CrCl 30-49 mL/min), but for severe renal impairment (CrCl 15-29 mL/min), the dose remains 15 mg with close monitoring 1, 2
• The International Society on Thrombosis and Haemostasis notes that severe renal impairment was an exclusion criterion in the ROCKET AF and EINSTEIN studies, making clinical experience extremely limited 4

Dosage Recommendations for Severe Renal Impairment

• For CrCl 15-29 mL/min, apixaban is the preferred option, with a dose of 2.5 mg twice daily, due to its lower renal elimination of 27% 3, 5
• Warfarin remains an alternative anticoagulant of choice for severe or end-stage renal disease, according to the American Heart Association, with dose adjustment to maintain INR 2.0-3.0 1, 6

Pharmacological Interactions to Verify

• Verify if the patient is taking P-glycoprotein inhibitors (amiodarone, verapamil, ketoconazole, quinidine, clarithromycin) that further increase rivaroxaban plasma levels 1, 4
• Concomitant use of rivaroxaban with P-glycoprotein inhibitors in patients with severe renal impairment should be avoided 1, 6

Mandatory Monitoring

• Renal function assessment with serum creatinine every 2-3 months in patients with moderate renal impairment, more frequently if severe 2, 3, 5
• Clinical monitoring for signs of bleeding at each visit, although specific details are not provided in the cited references 1, 2, 3, 4, 5, 6